{"name":"DURECT Corporation","slug":"durect","ticker":"DRRX","exchange":"NASDAQ","domain":"durect.com","description":"DURECT Corporation is a biopharmaceutical company focused on the development of innovative treatments for liver diseases and pain management. The company has a pipeline of products, including DUR-928, a small molecule drug candidate for the treatment of liver diseases, and SABER-Bupivacaine, a sustained release formulation of bupivacaine for the treatment of pain. DURECT has a strong presence in the hepatology and pain management markets, with a growing portfolio of products in development.","hq":"Cupertino, CA","founded":1998,"employees":"~75","ceo":"James E. Brown","sector":"Hepatology / Liver Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$123.4M","metrics":{"revenue":8000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"SABER-Bupivacaine patent cliff ($1.2B at risk)","drug":"SABER-Bupivacaine","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Bupivacaine HCl Treatment 1c","genericName":"Bupivacaine HCl Treatment 1c","slug":"bupivacaine-hcl-treatment-1c","indication":"Local anesthesia for surgical procedures","status":"phase_2"},{"name":"EN3270","genericName":"EN3270","slug":"en3270","indication":"Chronic pain","status":"phase_2"},{"name":"SABER-Bupivacaine","genericName":"SABER-Bupivacaine","slug":"saber-bupivacaine","indication":"Postoperative pain management","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Bupivacaine HCl Treatment 2c","genericName":"Bupivacaine HCl Treatment 2c","slug":"bupivacaine-hcl-treatment-2c","indication":"Local anesthesia for surgical procedures","status":"phase_2"},{"name":"DUR-928 Topical Solution","genericName":"DUR-928 Topical Solution","slug":"dur-928-topical-solution","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Bupivacaine HCl Treatment 1c","genericName":"Bupivacaine HCl Treatment 1c","slug":"bupivacaine-hcl-treatment-1c","phase":"phase_2","mechanism":"Bupivacaine HCl is a local anesthetic that works by blocking sodium channels in nerve fibers to prevent the initiation and transmission of nerve impulses.","indications":["Local anesthesia for surgical procedures","Pain management for postoperative pain"],"catalyst":""},{"name":"Bupivacaine HCl Treatment 2c","genericName":"Bupivacaine HCl Treatment 2c","slug":"bupivacaine-hcl-treatment-2c","phase":"phase_2","mechanism":"Bupivacaine HCl is a local anesthetic that blocks nerve impulses, preventing pain.","indications":["Local anesthesia for surgical procedures"],"catalyst":""},{"name":"DUR-928 Topical Solution","genericName":"DUR-928 Topical Solution","slug":"dur-928-topical-solution","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EN3270","genericName":"EN3270","slug":"en3270","phase":"phase_2","mechanism":"EN3270 is a small molecule that targets the sigma-1 receptor.","indications":["Chronic pain"],"catalyst":""},{"name":"SABER-Bupivacaine","genericName":"SABER-Bupivacaine","slug":"saber-bupivacaine","phase":"phase_3","mechanism":"SABER-Bupivacaine is a sustained-release formulation of bupivacaine, a local anesthetic that blocks nerve impulses.","indications":["Postoperative pain management"],"catalyst":""}],"recentEvents":[{"date":"2023-02-22","type":"deal","headline":"DURECT Enters into Licensing Agreement with AcelRx Pharmaceuticals for SABER-Bupivacaine","summary":"DURECT Corporation entered into a licensing agreement with AcelRx Pharmaceuticals for the development and commercialization of SABER-Bupivacaine.","drugName":"SABER-Bupivacaine","sentiment":"positive"},{"date":"2022-11-14","type":"trial","headline":"DURECT Announces Positive Topline Results from Phase 2 Clinical Trial of SABER-Bupivacaine in Pain Management","summary":"DURECT Corporation announced positive topline results from its Phase 2 clinical trial of SABER-Bupivacaine in patients with pain management.","drugName":"SABER-Bupivacaine","sentiment":"positive"},{"date":"2022-03-15","type":"trial","headline":"DURECT Announces Positive Topline Results from Phase 2 Clinical Trial of DUR-928 in NASH","summary":"DURECT Corporation announced positive topline results from its Phase 2 clinical trial of DUR-928 in patients with non-alcoholic steatohepatitis (NASH).","drugName":"DUR-928","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNa1JuTHpYUnhqb2cyZHNJbHRSVFFlMWQ2aDVrZjhLbGw1akhRdGJ2c3UzLXB5eGkzXzRDYjE3VnRadmVuNEtaWlAtSjFsSHRVbDhsQTI4OWpua05ZcUl1b0VRd3ZsdDRsWkZMU3g0LUZ0ZWFCWG5hejQwVk4tQzdyLXg1NVJFWEJpaTlxRF93?oc=5","date":"2025-09-12","type":"deal","source":"orrick.com","summary":"DURECT Acquired by Bausch Health Companies Inc. - orrick.com","headline":"DURECT Acquired by Bausch Health Companies Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxNdmk1RFFFWVNST0VNRHVUdlUtcF81SXpYMG9Qd002UUNCN1NxcW4tYWV3YWdvaDB3VlpuRXI2QXMzZ3dzOXlXZjZMTnJNVXlGWnhNZWJuRFhSc2x3NEZVN051YnpJMXQtOHFJOVZqTVV3dUNBWVZxekNHYVlaNGNSY2E1V3U2el93NzFENWx5Z2RUYzVkY0J2aGpjcTBaSzBDQmZ1S0s0ZWliUTBVbFdsaDV5bkVfaUhWb0hyNTBuVEpjRGdlS2UxX2o0UUVCMGxWUUZ1MUwxbG9pT3h6bExfcXVfSUJoRnBMeEI4VnJIUQ?oc=5","date":"2025-09-11","type":"pipeline","source":"PR Newswire","summary":"Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio - PR Newswire","headline":"Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNbFh1REVLdHI5Y1dZWVFkMlJwT2Y5cm5ydDlrem1qLW5rNjVIOUg1MHhmeUZEWFRmSkR3Z1B6Q0gtZ01peEtOak5yQ3UtclY4TjJxdDNncjc2ekRZanlnMEktTWhscDQ1cmRRWk92UnZRblg5NXVXT1FnQnNkYkhubW5WX29acUxlRGlwMW5iOA?oc=5","date":"2025-08-26","type":"pipeline","source":"Yahoo Finance","summary":"Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025 - Yahoo Finance","headline":"Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxNTUc2SHZsNGwyaURlQ0VzbXltMFZfcW9mbngyOG5wc3B4UzlSYm5tLWVveV9EZEZ4elhWd3NMQUxtV0hQa3g1ci16bXRkOW5zS2p5WGp4MlluODhESVNQc0lHZ1NKNEs5d1I1X19xZG9sU3J4WHZjbGduRkRvZndoSVotX0NIQ19PRk0wUmkwazB4Nl9XcEFCcXZJNkMwNE9sYzlocTdENlhsNDVyZUg3MUc2N3F2eVB6QTFhUFZjd01NQ2JNMWYySDVUMjc1Nmpic1M0dURVVlJiaHRwd3FseGhZZWtsSkFFVF9kQ1h1UVRRV2pHNEQ0dm1YejJUZ2NxTXI0dzBYYlVpTGpka0RzMEJmcEo0LXVYdU04?oc=5","date":"2025-07-29","type":"deal","source":"PR Newswire","summary":"Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease - PR Newswire","headline":"Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients wi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQQk5JTWpVZmdxQ2c0Rk1BU0ROdWtIMW5XNlgwR0cwQnZmdGZlalJ2WFB0NTJoUW5qRlUzLUlSU0tFc3NvbE9zNGVxNnA3ZThwaEgzTWVJc004TWpMV0VOcy0zb2NLNHN2d3hIbERZX2R6MDhoUVpvV2FrUXM1M1Q5SWdCb3l5UXkydVBDWGdaVG51V2d0QVlwa1JuQWRDUDNNY3c?oc=5","date":"2025-07-29","type":"pipeline","source":"Stock Titan","summary":"Bausch Health launches tender for DURECT with cash and milestone CVR - Stock Titan","headline":"Bausch Health launches tender for DURECT with cash and milestone CVR","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-03-15","type":"pipeline","source":"simplywall.st","summary":"DURECT Corporation (NASDAQ:DRRX) Is Expected To Breakeven In The Near Future - simplywall.st","headline":"DURECT Corporation (NASDAQ:DRRX) Is Expected To Breakeven In The Near Future","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNU256VzZPQlFoSW9fdGFkNjdsV2c5X1FtZm5GOURXb3RQRklVd1NTTk9VMi1VS052SGVsRG13ZXlDbHh1amZyY0dnaUNGRW01bm1KbllMZHZDckg0NXdaTHJyU1pqVllfSmhlY0FSSlRNNkpNek9iaHlub1pWWlRveUNpODl3amM2NUJJQWQ1SHUtT1B1NVJHN3JBdmdfWWxKeXI4YXo4NHhXd3RrS3FWWU03UU8xaXpuVnhnLTYxalZITkd4RldEMzhxYS1YR2VXUjJGZmQ2REVTbXRlS2V2YQ?oc=5","date":"2025-01-28","type":"trial","source":"PR Newswire","summary":"DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence - PR Newswire","headline":"DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE0wV1FwVU9mLXh4WEhEUmJpaVJObjNMOG5KYU9HVHRMSjJienVjUG9MbUJpTXRlcXQ0QzVPSkJYdkpXb1NJX3pDMTVmQVZDdHkxRHJicVhKOWllZUJxczhJ?oc=5","date":"2019-11-29","type":"pipeline","source":"ChartMill","summary":"DRRX Stock Price, Quote & Chart | DURECT CORPORATION (NASDAQ:DRRX) - ChartMill","headline":"DRRX Stock Price, Quote & Chart | DURECT CORPORATION (NASDAQ:DRRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQVzdsekJJZ2Rjd05oaTU4WDhaLUVRalF1ODBMYnE5anVHVjNoamM5LVNxSHl0QXVHT3dFdTBITS1XZDd5azNKcC1od1ZoaWVnbVFFdjZZTm55a1JJNDVWWjVlOXJ5LVcxcXVYOWlrMnl6TTNxWEY2Ym1mMnhaUzI0ZW96a1RRVWRhZ2pjeElDdUJ6VmVUVjhSdHJ6R1NWQWd0bF9lTjZJdjVYeHNKdGZTdkprX3J3WnBYekY2ODdqS3lzMlpEOEhWXw?oc=5","date":"2010-06-08","type":"pipeline","source":"Fierce Biotech","summary":"Hospira and DURECT Corporation Sign Agreement to Develop and Commercialize POSIDUR(TM) (SABER(TM)-Bupivacaine) in the U.S. and C - Fierce Biotech","headline":"Hospira and DURECT Corporation Sign Agreement to Develop and Commercialize POSIDUR(TM) (SABER(TM)-Bupivacaine) in the U.","sentiment":"neutral"}],"patents":[{"drugName":"SABER-Bupivacaine","drugSlug":"bupivacaine","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":5,"phaseCounts":{"phase_2":4,"phase_3":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Gilead Sciences","Merck & Co.","Bayer AG"],"therapeuticFocus":["Hepatology","Pain Management"],"financials":null,"yahoo":null}